PSE Product Makes “Highly” Tamper-Resistant Claim With 100% Out Of Reach
This article was originally published in The Tan Sheet
Executive Summary
Westport Pharmaceuticals says a claim of being “highly” resistant to PSE-extraction distinguishes Zephrex-D from the competition, but the distinction alone is not adding up to market-share gains in the nonprescription nasal decongestant space.
You may also be interested in...
Extended-Release PSE Points Acura At First Tamper-Resistant Formulation NDA
Like extended-release PSE products already available OTC, a product with tamper-resistant formulation labeling must go through the NDA process. “The novelty of this to the FDA is what testing you do to demonstrate meth resistance … what labeling do you put on a product?” says Acura CEO Bob Jones.
Extended-Release PSE Points Acura At First Tamper-Resistant Formulation NDA
Like extended-release PSE products already available OTC, a product with tamper-resistant formulation labeling must go through the NDA process. “The novelty of this to the FDA is what testing you do to demonstrate meth resistance … what labeling do you put on a product?” says Acura CEO Bob Jones.
Tamper-Resistant PSE Takes Big Pharma Stage: Bayer Licenses Acura’s Formulation
Bayer gains exclusive worldwide license to Acura Pharmaceuticals’ Impede technology for use in a pseudoephedrine-containing product resistant to extraction to make methamphetamine. The deal is Acura’s first licensing, and the first move toward tamper-resistant PSE by a major pharma firm.